Gour Medical SA engages in the development and commercialization of veterinary drugs. More Details
Weak fundamentals or lack of information.
Share Price & News
How has Gour Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MLGML is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 36% a week.
Volatility Over Time: MLGML's weekly volatility (36%) has been stable over the past year, but is still higher than 75% of French stocks.
7 Day Return
1 Year Return
Return vs Industry: MLGML underperformed the French Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: MLGML underperformed the French Market which returned 48.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Gour Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Gour Medical undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Gour Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Gour Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Gour Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gour Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Gour Medical performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
Earnings and Revenue History
Quality Earnings: Insufficient data to determine if MLGML has high quality earnings.
Growing Profit Margin: Insufficient data to determine if MLGML's profit margins have improved over the past year.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MLGML's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare MLGML's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if MLGML's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: MLGML has a negative Return on Equity (0%), as it is currently unprofitable.
How is Gour Medical's financial position?
In this section we usually analyse Gour Medical's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Gour Medical has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
What is Gour Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MLGML's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MLGML's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MLGML's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MLGML's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MLGML's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Serge Goldner serves as Chairman, Chief Executive Officer and Member of Executive Board at Gour Medical SA. Mr. Goldner served as the Chief Financial Officer of Immune Pharmaceuticals, Inc. He was the ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Gour Medical SA's company bio, employee growth, exchange listings and data sources
- Name: Gour Medical SA
- Ticker: MLGML
- Exchange: ENXTPA
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €339.239k
- Shares outstanding: 3.33m
- Website: https://www.gour-medical.com
- Gour Medical SA
- 5, rue de Castiglione
Gour Medical SA engages in the development and commercialization of veterinary drugs. The company develops various medicines and food supplements to enhance the health of mature pets. Its product portfolio...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 20:14|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.